ALLMedicine™ Acute Promyelocytic Leukemia Center
Research & Reviews 2,783 results
https://doi.org/10.1371/journal.pone.0251011
PloS One; Yoo KH, Kim HJ et. al.
May 7th, 2021 - The clinical characteristics and therapeutic strategy in acute myeloid leukemia (AML) are influenced by patients' age. We evaluated the impact of age on remission induction therapy for AML. We retrospectively analyzed 3,011 adult AML patients iden...
https://doi.org/10.1007/s12094-021-02625-6 10.3390/cancers11101591 10.1038/s41375-018-0338-z 10.1038/leu.2016.237 10.1016/j.ebiom.2015.04.006 10.3390/cancers11091311 10.1111/bjh.16420 10.1002/ajh.25573 10.1080/10428194.2020.1742910 10.1007/s00277-017-3096-5 10.1007/s12185-017-2211-7 10.1016/j.htct.2019.12.001 10.1016/j.leukres.2020.106358 10.1515/med-2019-0074 10.1007/s00277-017-3130-7 10.1007/s00432-019-03076-x 10.1007/s00277-017-3216-2 10.1016/j.clml.2018.11.004 10.1182/blood-2009-07-230805 10.1002/cncr.27650 10.1097/MD.0000000000009324 10.1016/j.clml.2019.10.003 10.1038/s41598-019-47937-4 10.3324/haematol.2016.162206 10.1016/j.clml.2019.08.006 10.1038/sj.leu.2402723 10.1182/blood-2018-07-866095 10.1182/blood-2006-04-015040 10.1128/mcb.20.17.6276-6286.2000
Clinical & Translational Oncology : Official Publication ... Chen X, Fan S et. al.
May 4th, 2021 - APL patients have recurrent alterations in FLT3, WT1, NRAS and KRAS. Gene mutations have a strong potential for involvement in pathogenesis and may have potential effects on the clinical manifestations. Gene mutations may even be associated with e...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094532
Journal of Medical Case Reports; Haghighat S, Rezvani A et. al.
May 4th, 2021 - Although life-threatening hemorrhage is a usual manifestation of acute promyelocytic leukemia (APL), thrombotic events seem to be more common in APL compared to other subtypes of acute leukemia. The treatment and prophylaxis of thrombosis are cont...
https://doi.org/10.1016/j.clml.2021.03.010
Clinical Lymphoma, Myeloma & Leukemia; Wang CY, Huang HH et. al.
May 1st, 2021 - Acute myeloid leukemia (AML) is a hematological malignancy originating from myeloid precursor cells, with different cytogenetic abnormalities, genetic mutations and diverse clinical prognoses. We investigated the clinical characteristics, treatmen...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071704
Drug Design, Development and Therapy; Zhang L, Yang XM et. al.
Apr 29th, 2021 - An oral tetra-arsenic tetra-sulfide (AS4S4) formula has been recommended as an outpatient post-remission treatment for Chinese adults with acute promyelocytic leukemia (APL) but limited data are available for children. In this exploratory study, w...
Guidelines 2 results
http://ascopubs.org/doi/10.1200/JCO.18.01468
de Haas, V.
Dec 2nd, 2018 - The College of American Pathologists (CAP) and the American Society of Hematology (ASH) developed an evidence-based guideline on the initial diagnostic work-up of acute leukemia (AL). Because of the relevance of this topic to the ASCO membership,.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.
Sep 13th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...
Drugs 23 results see all →
Clinicaltrials.gov 2,885 results
https://doi.org/10.1371/journal.pone.0251011
PloS One; Yoo KH, Kim HJ et. al.
May 7th, 2021 - The clinical characteristics and therapeutic strategy in acute myeloid leukemia (AML) are influenced by patients' age. We evaluated the impact of age on remission induction therapy for AML. We retrospectively analyzed 3,011 adult AML patients iden...
https://doi.org/10.1007/s12094-021-02625-6 10.3390/cancers11101591 10.1038/s41375-018-0338-z 10.1038/leu.2016.237 10.1016/j.ebiom.2015.04.006 10.3390/cancers11091311 10.1111/bjh.16420 10.1002/ajh.25573 10.1080/10428194.2020.1742910 10.1007/s00277-017-3096-5 10.1007/s12185-017-2211-7 10.1016/j.htct.2019.12.001 10.1016/j.leukres.2020.106358 10.1515/med-2019-0074 10.1007/s00277-017-3130-7 10.1007/s00432-019-03076-x 10.1007/s00277-017-3216-2 10.1016/j.clml.2018.11.004 10.1182/blood-2009-07-230805 10.1002/cncr.27650 10.1097/MD.0000000000009324 10.1016/j.clml.2019.10.003 10.1038/s41598-019-47937-4 10.3324/haematol.2016.162206 10.1016/j.clml.2019.08.006 10.1038/sj.leu.2402723 10.1182/blood-2018-07-866095 10.1182/blood-2006-04-015040 10.1128/mcb.20.17.6276-6286.2000
Clinical & Translational Oncology : Official Publication ... Chen X, Fan S et. al.
May 4th, 2021 - APL patients have recurrent alterations in FLT3, WT1, NRAS and KRAS. Gene mutations have a strong potential for involvement in pathogenesis and may have potential effects on the clinical manifestations. Gene mutations may even be associated with e...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094532
Journal of Medical Case Reports; Haghighat S, Rezvani A et. al.
May 4th, 2021 - Although life-threatening hemorrhage is a usual manifestation of acute promyelocytic leukemia (APL), thrombotic events seem to be more common in APL compared to other subtypes of acute leukemia. The treatment and prophylaxis of thrombosis are cont...
https://doi.org/10.1016/j.clml.2021.03.010
Clinical Lymphoma, Myeloma & Leukemia; Wang CY, Huang HH et. al.
May 1st, 2021 - Acute myeloid leukemia (AML) is a hematological malignancy originating from myeloid precursor cells, with different cytogenetic abnormalities, genetic mutations and diverse clinical prognoses. We investigated the clinical characteristics, treatmen...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071704
Drug Design, Development and Therapy; Zhang L, Yang XM et. al.
Apr 29th, 2021 - An oral tetra-arsenic tetra-sulfide (AS4S4) formula has been recommended as an outpatient post-remission treatment for Chinese adults with acute promyelocytic leukemia (APL) but limited data are available for children. In this exploratory study, w...
News 77 results
https://decisionpoint.medscape.com/oncology/viewarticle/936167
Sep 17th, 2020 - This transcript has been edited for clarity. Differentiation syndrome is a frequent complication while patients have active acute promyelocytic leukemia (APL). First of all, we need to mention that the diagnosis of differentiation syndrome is base...
https://www.medscape.com/viewarticle/934124
Jul 16th, 2020 - The estimated one third of patients with acute promyelocytic leukemia (APL) who are older than 60 years of age now enjoy a notably better prognosis than in years past, thanks to the introduction of all-trans retinoic acid (ATRA) and arsenic trioxi...
https://www.staging.medscape.com/viewarticle/917519
Aug 29th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...
https://www.medscape.com/viewarticle/917519
Aug 29th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...
https://www.mdedge.com/hematology-oncology/article/190803/leukemia-myelodysplasia-transplantation/fda-approves-generic-drugs-apl?channel=50519
HT Staff
Nov 16th, 2018 - Photo from Business Wire Fresenius Kabi’s arsenic trioxide The U. S.
